Seqens, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that it has been recognized as a Life Science Leader CMO Leadership Award recipient in the category of Regulatory for the midsize pharma and biotech industry sectors. This is the second year in a row that Seqens has been awarded multiple CMO Leadership Awards and the company has now won an award in every category in which the awards are given.
The awards will be presented at the CMO Awards Banquet and Reception March 18 at the W Hotel in New York City.
The CMO Leadership Awards are determined from industry data collected by Nice Insight. Nice Insight conducts an annual survey on pharmaceutical outsourcing practices to collect baseline customer awareness and customer perception of 100+ CMOs and 70+ CROs. Award categories include Quality, Productivity, Reliability, Innovation and Regulatory Record. The annual awards recognize those contract manufacturing organizations (CMOs) that are the most highly rated by industry respondents. This is particularly valuable for pharmaceutical and biopharmaceutical executives in evaluating potential partners for contract manufacturing.
Rob Wright, Chief Editor at Life Science Leader, said, “The fourth annual CMO Awards recognize the best and the brightest of CMOs in the market today, companies that have earned the respect and trust of executives responsible for making key outsourcing decisions. Seqens has been an award recipient for two years in a row, a testament to how committed the company is to partnership and high quality products on time and on budget.”
Ed Price, president and CEO of Seqens, added, “The importance we place on our relationships with our customers has never been stronger. Through our communication, our commitment to top quality and our investment in best practices, we show our value and work to earn our customers’ trust every day.”
Seqens is a custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), Seqens provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about Seqens, its proprietary NCE development activities and process R&D capabilities please visitwww.pcisynthesis.com.